Quick Answer
Akari Therapeutics Plc reported Operating Income Loss of -$17.28 million for the year ending 2025.
- Akari Therapeutics Plc showed an increase of +20.2% in Operating Income Loss from 2024 to 2025.
- This data is from Akari Therapeutics Plc's annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), Akari Therapeutics Plc's Operating Income Loss has declined by 668.8%.
- Historical annual values: Fiscal year 2025: -$17.28 million | Fiscal year 2024: -$21.64 million | Fiscal year 2023: -$16.81 million | Fiscal year 2022: -$23.09 million | Fiscal year 2021: -$17.21 million | Fiscal year 2020: -$17.98 million | Fiscal year 2019: -$16.96 million | Fiscal year 2018: -$20.79 million | Fiscal year 2017: -$37.78 million | Fiscal year 2016: -$27.25 million | Fiscal year 2015: -$30.58 million | Fiscal year 2014: -$1.92 million | Fiscal year 2013: -$3.61 million | Fiscal year 2012: -$3.67 million | Fiscal year 2011: -$2.25 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: